Global Health Ltd

- The document does not explicitly mention any current or planned fundraising through debt or equity. - The company has a well-capitalized balance sheet to fund future expansion and growth plans. - Capex of approximately INR 1,770 million was incurred during the nine months ended December 2023, primarily towards the Noida hospital project. - The company focuses on organic growth but remains open to growth opportunities beyond organic expansions, provided they meet their strategic criteria. - No specific details on issuing new debt or equity were disclosed in the provided transcript.

- Incurred capex of approx. INR 1,770 million for nine months ended December 2023; 66% (INR 1,170 million) toward Noida hospital project. - Noida hospital construction is on track with 82% superstructure completed; mechanical, electrical, and plumbing work underway. - Noida hospital expected to commence operations by end of FY25. - Plan to add 140-150 beds in Lucknow and 30-40 beds in Patna by end of March 2024. - Conversion of a floor in Medanta Gurugram from approx. 60 beds to daycare for medical oncology chemotherapy procedures. - Adding approx. 50 beds to mother and child unit in Gurugram. - Incorporated a SPV company (GHL Hospitals Limited) with DLF Limited to construct and operate a super-specialty Medanta Hospital in South Delhi. - Actively evaluating opportunities beyond current hospitals for expansion, subject to detailed due diligence and compliance.

- Strong volume-driven growth continues across both developing (Lucknow, Patna) and mature hospitals, with 13-17% growth in inpatient footfalls and occupied bed days reported recently. - Developing hospitals’ revenue share has increased significantly, evidencing strong expansion momentum. - Noida hospital opening by end of FY25 expected to add substantial capacity and revenue streams. - Bed expansions planned: 140-150 beds in Lucknow and 30-40 beds in Patna by March 2024; 60 beds in Gurgaon repurposed for daycare oncology and 50 beds added to mother-child unit. - Focus remains on balanced tariff increases, with growth primarily driven by volumes rather than aggressive tariff hikes. - Continued addition of doctors (253 in nine months) to support volume growth and service expansion. - Opportunities being explored in UP beyond Lucknow, including Noida and potentially Eastern and Western UP, indicating longer-term growth prospects. - OPD pharmacy business also registering strong revenue growth of 28% year-on-year.

- Medanta emphasizes long-term growth over quarterly optimization, focusing on annualized or longer-term performance. - Volume growth is the primary driver of revenue, with inpatient footfalls and occupied bed days showing double-digit YoY growth. - Developing hospitals (Lucknow, Patna) show strong revenue and EBITDA growth, with improving margins; Lucknow and Patna expected to add beds, fueling further growth. - Noida hospital project progressing, with operations expected by FY25 end; breakeven anticipated in 3-4 years, possibly faster due to design. - Margins expected to benefit from operational leverage as volumes increase on a fixed cost base, though input cost inflation and regulation could dilute margins. - Conservative tariff increases with focus on affordability; ARPOB growth moderate (~4% YoY), driven more by volume than price hikes. - Continued onboarding of doctors and capacity expansion expected to support sustainable volume and profit growth.

The transcript provided from Medanta – Global Health Limited's earnings call does not explicitly mention current or expected order book or pending orders. However, relevant insights related to growth plans and capacity expansions include: - Ongoing construction of the Noida hospital, expected to commence operations by end of FY25 with around 300 beds planned. - Addition of approximately 140-150 beds in Lucknow and 30-40 beds in Patna by March 2024. - Conversion of 60 beds into daycare for medical oncology chemotherapy in Gurugram and addition of around 50 beds in mother and child unit. - Incorporation of a special purpose vehicle (SPV) with DLF Limited for super-specialty hospital in South Delhi. - Management is actively exploring both organic expansion and inorganic opportunities, pending due diligence and regulatory approvals, such as for the Indore project. - No specific figures on order books or pending orders disclosed in the call or report.